It was a busy week for the biotech sector, with regulatory and pipeline updates. Sage Therapeutics SAGE was in focus after it ...

Have you been searching for a stock that might be well-positioned to maintain its earnings-beat streak in its upcoming report? It is worth considering Biogen Inc. (BIIB), which belongs to the Zacks ...

In a report released today, Brian Abrahams from RBC Capital maintained a Buy rating on Biogen (BIIB – Research Report), with a price target of ...

The FDA's approval is based on simulation data from multiple studies showing that maintenance dosing with Biogen???s Leqembi ...

The stock's fall snapped a five-day winning streak.

Citi analyst Geoff Meacham lowered the firm’s price target on Biogen (BIIB) to $160 from $190 and keeps a Neutral rating on the shares. Ahead ...

This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions ...

The 12-month price targets, analyzed by analysts, offer insights with an average target of $214.78, a high estimate of ...

Equities research analysts at Wedbush dropped their FY2024 EPS estimates for Biogen in a research report issued on Thursday, ...

Sage Therapeutics rejected a takeover offer from Biogen ( BIIB) and said it started a process to review its strategic ...

Check the time stamp on this data. Updated AI-Generated Signals for Biogen Inc. (BIIB) available here: BIIB. Type a few ...

Investors in Biogen Inc (Symbol: BIIB) saw new options become available this week, for the March 21st expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the BIIB ...